StockData
TRex Bio, Inc. logo

TRex Bio, Inc. (TRXB) company profile

TRXBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026
$10.00−0.77 (-7.15%)

Close on Nov 17, 2026Market cap $15.02MP/E –Yield –

About TRex Bio

Biological Products, (No Diagnostic Substances), SIC 2836

TRex Bio, Inc. is listed on Nasdaq under the ticker TRXB, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
TRex Bio, Inc.
Headquarters
South San Francisco, CA
Address
C/O Trex Bio, Inc., 269 East Grand Avenue Suite 300
Phone
(650) 567-5582
Website
trex.bio
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
TRXB
Exchange
Nasdaq
IPO date
Oct 9, 2026
Filer category
<br>Emerging growth company
SEC CIK
2139097
CUSIP
89531N100
ISIN
US89531N1000
FIGI
BBG00SHZYM97
Share class FIGI
BBG00SHZYMB4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marion Johnston Erwin Jr.Chief Executive Officer, Director–
Ariella KelmanChief Medical Officer–
Laura BernerChief Operating Officer168,574
Brandon HantsChief Financial Officer–
Ali ZarrinChief Scientific Officer18,111
Joel S. MarcusDirector41,871
Peter HirthDirector38,202
Carol Giltner GallagherDirector251,471
Michael Jay RossDirector–
Travis Alan CoyDirector–
Julie Ann GilmoreDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 9, 2026
Offer price
$14.00
Securities offered
8,333,334
Gross proceeds
$116.67M
Exchange
Nasdaq
First trading day
Oct 9, 2026
First-day close
$14.000.0%
Lock-up ends (est.)
Apr 7, 2027

“The initial public offering price is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?